MedTech Dive August 12, 2024
C2N Diagnostics announced the partnership after recently receiving an investment from the Japanese drugmaker Eisai, which developed the Alzheimer’s drug Leqembi with Biogen.
Dive Brief:
- Unilabs has struck a deal to distribute C2N Diagnostics’ Alzheimer’s disease blood tests in Europe and certain other regions, the companies said last week.
- C2N has developed blood tests for detecting amyloid plaques and neurofibrillary “tau” tangles, which the company said are “pathological hallmarks of Alzheimer’s disease.” The tests provide a non-invasive way to evaluate markers of mild cognitive impairment and dementia.
- The PrecivityAD amyloid plaque test received a CE mark in 2020. Unilabs expects to make C2N tests available to its customers in the coming months.
Dive Insight:
Amyloid PET scans and...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices